Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 87 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 87 versus QDOLO.
FENTANYL-87 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing cAMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life is approximately 3–12 hours (mean 7 hours) in adults; prolonged to up to 20–30 hours in elderly, critically ill, or patients with hepatic impairment. Context-sensitive half-life increases with infusion duration.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism (>90%) to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for approximately 75% of total elimination, with about 9% excreted unchanged in urine. Fecal excretion is minimal (<9%).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist